Cargando…
Treatment Options for Troublesome Itch
Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412524/ https://www.ncbi.nlm.nih.gov/pubmed/36015170 http://dx.doi.org/10.3390/ph15081022 |
_version_ | 1784775515322712064 |
---|---|
author | Toyama, Sumika Tominaga, Mitsutoshi Takamori, Kenji |
author_facet | Toyama, Sumika Tominaga, Mitsutoshi Takamori, Kenji |
author_sort | Toyama, Sumika |
collection | PubMed |
description | Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent pathways may play roles in chronic itch. Therefore, antihistamines are not always effective in the treatment of patients with chronic itch. The development of biologics and κ-opioid receptor (KOR) agonists has contributed to advances in the treatment of itch; however, since biologics are expensive for patients to purchase, some patients may limit or discontinue their use of these agents. Furthermore, KOR agonists need to be prescribed with caution due to risks of side effects in the central nervous system. Janus kinase (JAK) inhibitors are sometimes associated with side effects, such as infection. In this review, we summarize antidepressants, antineuralgics, cyclosporine A, antibiotics, crotamiton, phosphodiesterase 4 inhibitor, botulinum toxin type A, herbal medicines, phototherapy, and acupuncture therapy as itch treatment options other than antihistamines, biologics, opioids, and JAK inhibitors; we also explain their underlying mechanisms of action. |
format | Online Article Text |
id | pubmed-9412524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94125242022-08-27 Treatment Options for Troublesome Itch Toyama, Sumika Tominaga, Mitsutoshi Takamori, Kenji Pharmaceuticals (Basel) Review Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent pathways may play roles in chronic itch. Therefore, antihistamines are not always effective in the treatment of patients with chronic itch. The development of biologics and κ-opioid receptor (KOR) agonists has contributed to advances in the treatment of itch; however, since biologics are expensive for patients to purchase, some patients may limit or discontinue their use of these agents. Furthermore, KOR agonists need to be prescribed with caution due to risks of side effects in the central nervous system. Janus kinase (JAK) inhibitors are sometimes associated with side effects, such as infection. In this review, we summarize antidepressants, antineuralgics, cyclosporine A, antibiotics, crotamiton, phosphodiesterase 4 inhibitor, botulinum toxin type A, herbal medicines, phototherapy, and acupuncture therapy as itch treatment options other than antihistamines, biologics, opioids, and JAK inhibitors; we also explain their underlying mechanisms of action. MDPI 2022-08-19 /pmc/articles/PMC9412524/ /pubmed/36015170 http://dx.doi.org/10.3390/ph15081022 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Toyama, Sumika Tominaga, Mitsutoshi Takamori, Kenji Treatment Options for Troublesome Itch |
title | Treatment Options for Troublesome Itch |
title_full | Treatment Options for Troublesome Itch |
title_fullStr | Treatment Options for Troublesome Itch |
title_full_unstemmed | Treatment Options for Troublesome Itch |
title_short | Treatment Options for Troublesome Itch |
title_sort | treatment options for troublesome itch |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412524/ https://www.ncbi.nlm.nih.gov/pubmed/36015170 http://dx.doi.org/10.3390/ph15081022 |
work_keys_str_mv | AT toyamasumika treatmentoptionsfortroublesomeitch AT tominagamitsutoshi treatmentoptionsfortroublesomeitch AT takamorikenji treatmentoptionsfortroublesomeitch |